Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Calliditas Therapeutics AB
Calliditas Therapeutics AB
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Bevel edge or radius edge flat face tablets: Which is better for greater consumer acceptance?
Consumers and patients should perceive that their tablets are easy to swallow and devoid of any undesirable taste. Tablet manufacturers can influence acceptance of by producing...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Research & Development
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon
China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression
Regulatory
EMA issues positive opinion on Calliditas' orphan drug
Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients
Full details from Calliditas Therapeutics’ Phase 3 study released
Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Drug Delivery
Chinese NMPA accepts Calliditas' partner Everest Medicines NDA
Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people
Calliditas budesonide therapy approved to reduce proteinuria
Proteinuria is associated with IgAN, however it has not yet been established whether the therapy slows kidney function decline in patients with the condition
Regulatory
Calliditas receives fast track FDA designation for PBC candidate
The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing
Calliditas and Everest Medicines enter $120m development deal in China
The agreement gives Everest Medicines exclusive rights to develop and commercialise Nefecon in five countries in East Asia
Subscribe now